presentation to path (seattle, washington dc and san francisco), 23-may-14
DESCRIPTION
Presentation to PATH staff on 23-May-14. Delivered in Seattle with a video link to Washington and audio link to San Francisco. Download the presentation for the speech narrative that is contained in the notes to the slides.TRANSCRIPT
![Page 1: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/1.jpg)
The ColaLife Operational Trial in Zambia (COTZ)Prepared for PATH by Simon Berry 23-May-
14
![Page 2: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/2.jpg)
What is ColaLife and who am I?
ColaLife is a charity registered in the UKCharity number: 1142516
• No paid employees• Five voluntary trustees• Focus on saving children’s lives• Independent• Our only project is in Zambia• Looking for global impact through
• Disruptive innovation• Generating robust evidence• Sharing findings and learning
• No commercial interest
2009
2010
2011
2012
2013
1985
![Page 3: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/3.jpg)
The ColaLife team
2009
2010
2011
2012
2013
1985
Rohit Ramchandani
Jane Berry
![Page 4: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/4.jpg)
Our starting point
Coca-Cola seems to get everywhere in developing countries, yet life-saving medicines don't. Why?
![Page 5: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/5.jpg)
impact Mothers in underserved rural communities increase use of ORS and Zinc in home treatment of diarrhoea
purposeTarget communities in two under-served rural districts have improved access to ORS and Zinc
outputsProfit-driven supply chains improve availability of ADKs (anti-diarrhoea kits) in targeted communities in two underserved rural districts
Mothers/care-givers demonstrate awareness of ADKs and the benefits of the contents (ORS, Zinc and Soap)
access = ADK in the hand of an aware mother/care-giver
Availability = ADK in stock in retail outlets at community level
Generating robust evidence - the COTZ results framework
![Page 6: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/6.jpg)
Dec 2011
The COTZ trial timeline
![Page 7: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/7.jpg)
Early 2012 | Pre-trial focus group work
What we learnt
Litre sachets are too big
Measuring water was an issue
Willingness to pay
Preferred branding
![Page 8: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/8.jpg)
The Kit Yamoyo benefits
Kit Yamoyo• Attractive
![Page 9: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/9.jpg)
The Kit Yamoyo benefits
Kit Yamoyo• Attractive• ORS sachets are 200ml
![Page 10: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/10.jpg)
The Kit Yamoyo benefits
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
![Page 11: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/11.jpg)
The Kit Yamoyo benefits
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
• A measuring device for the water
![Page 12: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/12.jpg)
The Kit Yamoyo benefits
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
• A measuring device for the water
• A mixing device
![Page 13: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/13.jpg)
The Kit Yamoyo benefits
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
• A measuring device for the water
• A mixing device• A storage device (the
soap tray is a lid)
![Page 14: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/14.jpg)
The Kit Yamoyo benefits
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
• A measuring device for the water
• A mixing device• A storage device (the
soap tray is a lid)• A cup
![Page 15: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/15.jpg)
The COTZ trialResearch Design & Methodology
Quasi-experimental, pre-test, post test design baseline, midline and endline surveys
Target groups: Care-givers of under-5 children and private community retailers
Four Districts – two intervention districts and two matched comparator districts
Sample sizes:625 HH per district40 retailers per district
Vouchers used to launch the product
![Page 16: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/16.jpg)
The COTZ trialDistribution infrastructure and value chain
Pharmanova MSL Coca-Cola wholesalers• Standard Sales (2)• Isusya’s
Approximately 85 retailers across Katete and Kalomo
Manufacture & Assembly
Lusaka to District
District to Retailers
Mothers & Care-givers
![Page 17: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/17.jpg)
>26kkits sold into the two remote rural trial areas in 12 months.
![Page 18: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/18.jpg)
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
![Page 19: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/19.jpg)
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
![Page 20: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/20.jpg)
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
![Page 21: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/21.jpg)
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points to 92%.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
![Page 22: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/22.jpg)
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points to 92%.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
4%Only 4% of kits went into Coca-Cola crates. It was the space in the market not the space in the crates that was important.
![Page 23: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/23.jpg)
Our award-winning idea……
![Page 24: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/24.jpg)
Our award-winning idea……what happened in practice
![Page 25: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/25.jpg)
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points to 92%.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
4%Only 4% of kits went into Coca-Cola crates. It was the space in the market not the space in the crates that was important.
6International awards for health and design innovation & 6 countries interested in replication.
![Page 26: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/26.jpg)
Awards | The Kit Yamoyo has won many global awards
In Sep-13 it was featured at the UN General Assembly as a breakthrough innovation in Child Health.In Mar-14 it was show-cased by PATH and PSI in their Best Buys for Global Health initiative.
![Page 27: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/27.jpg)
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points to 92%.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
4%Only 4% of kits went into Coca-Cola crates. It was the space in the market not the space in the crates that was important.
6International awards for health and design innovation & 6 countries interested in replication.
...Request access to our findingscolalife.org/ openaccess
![Page 28: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/28.jpg)
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points to 92%.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
4%Only 4% of kits went into Coca-Cola crates. It was the space in the market not the space in the crates that was important.
6International awards for health and design innovation & 6 countries interested in replication.
...Request access to our findingscolalife.org/ openaccess
![Page 29: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/29.jpg)
ORSReduce number of sachets to 4
NOTE: This will also enhance adherence
ZincProduce locally
Only include blister pack
SoapProduce locally
Leaflet PackagingRemove constraint of fitting in Coca-Cola crate
Produce locally
Produce re-fill option
Oct 2013 | Incorporating the learning into the scale-up
![Page 30: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/30.jpg)
Learning: number of Kit Yamoyo ORS sachets used
![Page 31: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/31.jpg)
ORSReduce number of sachets to 4
NOTE: This may also enhance adherence to the combined therapy
ZincProduce locally
Only include blister pack
SoapProduce locally
Leaflet PackagingRemove constraint of fitting in Coca-Cola crate
Produce locally
Produce re-fill option
4Oct 2013 | Incorporating the learning into the scale-up
![Page 32: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/32.jpg)
Learning: Kit Yamoyo Zinc adherence – days Zinc taken
![Page 33: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/33.jpg)
Designing for better Zinc adherence
![Page 34: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/34.jpg)
ORSReduce number of sachets to 4
This may also enhance adherence to the combined therapy
ZincProduce locally
Design the blister pack to enhance adherence to the 10-day regime
Blister pack needs no box
SoapProduce locally
Leaflet PackagingRemove constraint of fitting in Coca-Cola crate
Produce locally
Produce re-fill option
4Oct 2013 | Incorporating the learning into the scale-up
![Page 35: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/35.jpg)
ORSReduce number of sachets to 4
This may also enhance adherence to the combined therapy
ZincProduce locally
Design the blister pack to enhance adherence to the 10-day regime
Blister pack needs no box
SoapProduce locally
Leaflet PackagingRemove constraint of fitting in Coca-Cola crate
Produce locally
Produce re-fill option
4Oct 2013 | Incorporating the learning into the scale-up
![Page 36: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/36.jpg)
ORSReduce number of sachets to 4
This may also enhance adherence to the combined therapy
ZincProduce locally
Design the blister pack to enhance adherence to the 10-day regime
lister pack needs no box
SoapProduce locally
LeafletSimplify – single fold.Same leaflet for all formats
PackagingRemove constraint of fitting in Coca-Cola crate
Produce locally
Produce re-fill option
4Oct 2013 | Incorporating the learning into the scale-up
![Page 37: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/37.jpg)
4Revised Kit Yamoyo leaflet
![Page 38: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/38.jpg)
ORSReduce number of sachets to 4
This may also enhance adherence to the combined therapy
ZincProduce locally
Design the blister pack to enhance adherence to the 10-day regime
Blister pack needs no box
SoapProduce locally
LeafletSimplify – single fold.Same leaflet for all formats
PackagingRemove constraint of fitting in Coca-Cola crate. Only 4% of retailers used this option
Produce locally
Produce re-fill option
4Oct 2013 | Incorporating the learning into the scale-up
![Page 39: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/39.jpg)
The screw-top The flexi-pack
![Page 40: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/40.jpg)
Format comparison
![Page 41: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/41.jpg)
TARGET unsubsidised retail costs (Kwacha)
Screw-top Flexi with soap Flexi w/out soap
Components
ORS (4 sachets) 0.9000 0.9000 0.9000
Zinc (1 blister pack of 10 tablets) 1.0000 1.0000 1.0000
Soap (25g anti-bacterial) 0.4400 0.4400 0
Leaflet 0.2000 0.2000 0.2000
Packaging
Container 0.9100 0.2000 0.2000
Bags and carton (per kit) 0.1200 0.0240 0.0240
Assembly 0.5000 0.2500 0.2500
TOTAL 4.0700 3.0140 2.5740
MSRP 8.00 6.00 5.00
Assumed margins: Manufacturer/distributor 20%; Wholesaler 20%; Retailer 35%
![Page 42: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/42.jpg)
Scale-up framework
Community-based marketing (all markets)
Not yet commercial
markets
Commercial markets
KZF/iDEPharmanova
Monitoring & Learning
Not yet commercial
markets
Collaborators
![Page 43: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/43.jpg)
colalife.org
[email protected]@[email protected]
The slides that follow this one may be of interest but are not essential reading
![Page 44: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/44.jpg)
The data contained in this presentation are unpublished and based on preliminary analysis of data from the ColaLife Operational Trial in Zambia (COTZ). Final calculations may vary and will be published in peer reviewed literature in due course.
In the interim, the following citation may be used: Ramchandani, R. et al. (2014). ColaLife Operational Trial Zambia (COTZ) Evaluation. Johns Hopkins Bloomberg School of Public Health, Baltimore.
Related correspondence should be sent to Rohit Ramchandani ([email protected]) and copied to Simon Berry ([email protected]).
A note on the data contained within this presentation
![Page 45: Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14](https://reader035.vdocuments.us/reader035/viewer/2022062702/554b9671b4c9052d448b49e2/html5/thumbnails/45.jpg)